The JAK inhibitor of AbbVie successfully passed CI among patients with rheumatoid arthritis

news

The experimental oral preparation of AbbVie demonstrated efficacy in the treatment of rheumatoid arthritis among patients who did not respond to standard treatment. The new drug, upadacitinib (upadacitinib) belongs to the class of JAK-inhibitors, writes Reuters.
Within 12-week clinical trials, upitcitinib was compared with placebo in patients with moderate to severe forms of rheumatoid arthritis.Among patients receiving upacitinib at a dosage of 15 mg and 30 mg, a 20% reduction in symptom severity was documented in 64% and 66%, respectively. In the placebo group, this indicator did not exceed 36%.
The authors of the study note that the data obtained indicate the superiority of upacitinib over baricitinib (baricitinib), a JAK inhibitor developed by Eli Lilly. It should be noted that only one drug of this class is represented on the market today - the tofacitinib of Pfizer.

A source:

Remedium